

Basic Science: (June 2006)

1. Adams SA, Matthews CE, Hebert JR, Moore CG, Cunningham JE, Shu XO, Fulton J, Gao YT, Zheng W. Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study [Abstract]. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 1170–1178.
2. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Furuta E, Iizumi M, Mohanta S, Watabe M, Chalfant C, Watabe K. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells [Abstract]. *Cancer Res* 2006; **66**: 5934–5940.
3. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy [Abstract]. *Cancer Res* **66**: 6421–6431.
4. Cellai C, Laurenzana A, Vannucchi AM, Caporale R, Paglierani M, Di Lollo S, Pancrazzi A, Paoletti F. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086 [Abstract]. *Brit J Cancer* 2006; **94**: 1637–1642.
5. Cui YK, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SAW. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance [Abstract]. *Cancer Res* 2006; **66**: 5950–5959.
6. den Hollander P, Kumar R. Dynein light chain 1 contributes to cell cycle progression by increasing cyclin-dependent kinase 2 activity in estrogen-stimulated cells [Abstract]. *Cancer Res* 2006; **66**: 5941–5949.
7. Dieudonne MN, Bussiere M, Dos Santos E, Leneuve MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells [Abstract]. *Biochem Biophys Res Commun* 2006; **345**: 271–279.
8. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen [Abstract]. *Oncogene* 2006; **25**: 3994–4008.
9. Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer [Abstract]. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 1153–1158.
10. Glinsky GV. Genomic models of metastatic cancer – Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated polycomb group (PcG) protein chromatin silencing pathway [Abstract]. *Cell Cycle* 2006; **5**: 1208–1216.
11. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells [Abstract]. *Breast Cancer Res Treat* 2006; **97**: 263–274.
12. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis [Abstract]. *J Clin Invest* 2006; **116**: 1561–1570.
13. Kataoka N, Cai QY, Wen WQ, Shu XO, Jin F, Gao YT, Zheng W. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women [Abstract]. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 1148–1152.
14. Kijima I, Phung S, Hur G, Kwok SL, Chen SU. Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression [Abstract]. *Cancer Res* 2006; **66**: 5960–5967.

15. Klinakis A, Szaboics M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice [Abstract]. *Proc Natl Acad Sci USA* 2006; **103**: 9262–9267.
16. Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors [Abstract]. *Oncogene* 2006; **25**: 3325–3334.
17. Li SY, Rong MN, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features [Abstract]. *Cancer Lett* 2006; **237**: 272–280.
18. Li TH, Sotgia F, Vuolo MA, Lo MM, Yang WC, Pestell RG, Sparano JA, Lisanti MP. Caveolin-1 mutations in human breast cancer – Functional association with estrogen receptor alpha-positive status [Abstract]. *Am J Pathol* 2006; **168**: 1998–2013.
19. Li ZP, Wang CG, Jiao XM, Lu YN, Fu MF, Quong AA, Dye C, Yang JG, Dai MZ, Ju XM, Zhang ZP, Li AP, Burbelo P, Stanley ER, Pestell RG. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling [Abstract]. *Mol Cell Biol* 2006; **26**: 4240–4256.
20. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer [Abstract]. *J Clin Oncol* 2006; **24**: 2793–2799.
21. Liu SL, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells [Abstract]. *Cancer Res* 2006; **66**: 6063–6071.
22. Mo R, Rao SM, Zhu YJ. Identification of the MLL2 complex as a coactivator for estrogen receptor alpha [Abstract]. *J Biol Chem* 2006; **281**: 15714–15720.
23. Murphy LC, Watson PH. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? [Abstract]. *Endocr Relat Cancer* 2006; **13**: 327–334.
24. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang BW, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, Lonning S, Wakefield LM. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer [Abstract]. *Cancer Res* 2006; **66**: 6327–6335.
25. Naresh A, Long WW, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JMS, Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells [Abstract]. *Cancer Res* 2006; **66**: 6412–6420.
26. Rakha EA, Green AR, Powe DG, Roylance R, Ellis IO. Chromosome 16 tumor-suppressor genes in breast cancer [Abstract]. *Gene Chromosome Cancer* 2006; **45**: 527–535.
27. Rayala SK, Molli PR, Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity [Abstract]. *Cancer Res* 2006; **66**: 5985–5988.
28. Salvucci O, Bouchard L, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study [Abstract]. *Breast Cancer Res Treat* 2006; **97**: 275–283.
29. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: Tamoxifen-bound reactivated ER recruits distinctive corepressor complexes [Abstract]. *Cancer Res* 2006; **66**: 6370–6378.
30. Smith RA, Lea RA, Weinstein SR, Griffiths LR. Detection of rRNA levels for the estrogen alpha, estrogen beta and androgen nuclear receptor genes in archival breast cancer tissue [Abstract]. *Cancer Lett* 2006; **237**: 248–255.
31. Souzaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression [Abstract]. *Cancer Res* 2006; **66**: 6243–6249.
32. Spankuch B, Heim S, Kurunci-Csacsco E, Lindenau C, Yuan JP, Kaufmann M, Strebhardt K. Down-regulation of polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo [Abstract]. *Cancer Res* 2006; **66**: 5836–5846.
33. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells [Abstract]. *Cancer Res* 2006; **66**: 5648–5655.
34. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter [Abstract]. *J Biol Chem* 2006; **281**: 16272–16278.
35. Stredrick DL, Garcia-Closas M, Pineda MA, Bhatti P, Alexander BH, Doody MM, Lissowska J, Peplonska B, Brinton LA, Chanock SJ,

- Struewing JP, Sigurdson AJ. The ATM missense mutation p.Ser49Cys (c.146C > G) and the risk of breast cancer [Abstract]. *Hum Mutat* 2006; **27**: 538–544.
36. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCa and Src inhibitors [Abstract]. *Oncogene* 2006; **25**: 3286–3295.
37. To MD, Gokgoz N, Doyle TG, Donoviel DB, Knight JA, Hyslop PS, Bernstein A, Andrulis IL. Functional characterization of novel presenilin-2 variants identified in human breast cancers [Abstract]. *Oncogene* 2006; **25**: 3557–3564.
38. Toyo-oka K, Bowen TJ, Hirotsune S, Li ZR, Jain S, Ota S, Escoubet L, Bassett IG, Lozach J, Rosenfeld NG, Glass CK, Eisenman R, Ren B, Hurlin P, Wynshaw-Boris A. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of Myc overexpression [Abstract]. *Cancer Res* 2006; **66**: 5565–5573.
39. Ueda Y, Neel NF, Schutyser E, Raman D, Richmond A. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells [Abstract]. *Cancer Res* 2006; **66**: 5665–5675.
40. Vargo-Gogola T, Heckman BM, Gunther EJ, Chodosh LA, Rosen JM. P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland [Abstract]. *Mol Endocrinol* 2006; **20**: 1391–1405.
41. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Durst M, Kristiansen G, Huszka C, Knuchel R, Dahl E. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis [Abstract]. *Oncogene* 2006; **25**: 3479–3488.
42. Wang ZY, Zhang XT, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-alpha, hER-alpha 36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling [Abstract]. *Proc Natl Acad Sci USA* 2006; **103**: 9063–9068.
43. Yeh YT, Fu OY, Chen IF, Yang SF, Wang YY, Chuang HY, Su JH, Hou MF, Yuan SSF. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma [Abstract]. *Int J Cancer* 2006; **118**: 2943–2947.
44. Zhang YQ, Zhang BL. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness [Abstract]. *Cancer Res* 2006; **66**: 5592–5598.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia